Shares are up more than 30% and closing in on 6,500 trades in the morning session. $2.29 a share as of writing this post.
Ekso Bionics Receives FDA Clearance to Market its EksoNR Robotic Exoskeleton for Use with Multiple Sclerosis Patients
First FDA Cleared Exoskeleton for Rehabilitation Use in Patients with Multiple Sclerosis
RICHMOND, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR robotic exoskeleton for use with Multiple Sclerosis (MS) patients. EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, an indication which significantly expands the devices use to a broader group of patients.